...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Digestive diseases >Herbal Preparation STW 5 for Functional Gastrointestinal Disorders: Clinical Experience in Everyday Practice
【24h】

Herbal Preparation STW 5 for Functional Gastrointestinal Disorders: Clinical Experience in Everyday Practice

机译：用于功能性胃肠疾病的草药制备STW 5：日常做法的临床经验

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: The most common functional gastrointestinal disorders (FGID) are functional dyspepsia (FD) and irritable bowel syndrome (IBS), with a prevalence in the general population of 15-20% (FD) and 10% (IBS), respectively. The complexity of pathophysiologic mechanisms and limitations in therapeutic options make the management of FD and IBS patients a challenge in routine clinical practice. Summary: Syndromes classified as FGID frequently overlap, and coexist with gastroesophageal reflux disease (GERD). Patients with overlapping symptoms are more likely to seek medical care. The challenge for routine clinical practice is to find the best approach for treatment of multiple symptoms. STW 5, a combination of 9 herbal extracts, was shown to have multi-target effects: it normalizes the disturbed gastrointestinal motility, alleviates hypersensitivity, inhibits inflammation, suppresses gastric hypersecretion, and modulates the microbiota. Controlled randomized studies proved STW 5 to be efficacious both in FD and IBS, with control over the full spectrum of upper and lower gastrointestinal symptoms. STW 5 reduced concomitant heartburn in FD patients. STW 5 was well tolerated in the examined populations, independent of concomitant diseases and concomitant medication. Key Messages: The clinical use of the herbal preparation STW 5 in FD and IBS is evidence-based. STW 5 is an example for the concept of multi-target therapy. It offers treatment opportunities in routine clinical practice with high prevalence of overlap of FGID and concomitant GERD. Considering that FD and IBS are typically chronic and recurrent conditions, the clinically observed good tolerability and safety of STW 5 is an advantage. (C) 2018 The Author(s) Published by S. Karger AG, Basel.
机译：背景：最常见的功能性胃肠道障碍（FGID）是功能性消化不良（FD）和肠易肠综合征（IBS），分别具有15-20％（FD）和10％（IBS）的一般人群流行。病理生理机制的复杂性和治疗选择中的限制使FD和IBS患者的管理成为常规临床实践中的挑战。发明内容：归类为FGID的综合征经常重叠，并与胃食管反流疾病（GERD）共存。症状重叠的患者更有可能寻求医疗保健。常规临床实践的挑战是寻找治疗多种症状的最佳方法。 STW 5，9个草药提取物的组合具有多目标影响：使得令人不安的胃肠运动标准化，缓解过敏，抑制炎症，抑制胃脓乳，并调节微生物。受控随机研究证明了STW 5在FD和IBS中有效，控制在上层和下胃肠道症状的全谱。 STW 5减少了FD患者的伴随胃灼热。 STW 5在检查的群体中耐受良好，与伴随的疾病和伴随的药物无关。关键消息：在FD和IBS中的草药制备STW 5的临床应用是基于证据。 STW 5是多目标疗法概念的示例。它为常规临床实践提供了治疗机会，具有高患有壁重叠和伴随的GERD。考虑到FD和IBS通常是慢性和反复性的条件，临床观察到的良好耐受性和STW 5的安全性是一个优点。 （c）2018年由S. Karger AG，巴塞尔发布的提交人。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号